CAMK2A and osteosarcoma: Inhibition of CaMK2α using a pharmacological antagonist (KN93), specific siRNA, or the K42M kinase-dead construct (CaMK2α K42M) resulted in a significant decrease in the growth of osteosarcoma cells.